Continuous low-dose oral chemotherapy for adjuvant therapy of splenic hemangiosarcoma in dogs.

摘要: Background: Hemangiosarcoma (HSA) is a highly metastatic and often rapidly fatal tumor in dogs. At present, conventional adjuvant chemotherapy provides only modest survival benefit for treated Continuous oral administration of low-dose (LDC) has been suggested as an alternative to protocols. Therefore, we evaluated the safety effectiveness LDC using combination cyclophosphamide, etoposide, piroxicam therapy dogs with stage II HSA. Hypothesis: We hypothesized that could be safely administered HSA times would comparable those attained doxorubicin (DOX) chemotherapy. Animals: Nine splenic were enrolled study. Treatment outcomes also retrospectively 24 DOX chemotherapy. Methods: over 6-month period. Adverse effects treatment determined. The pharmacokinetics orally etoposide determined 3 Overall disease-free intervals compared between 9 LDC-treated DOX-treated dogs. Results: Dogs did not develop severe adverse effects, long-term 6 months was well-tolerated. Oral resulted detectable plasma concentrations peaked 30 60 minutes after dosing. Both median overall time interval 178 days. By comparison, 133 126 days, respectively. Conclusions: may effective high-dose HSA.